17th World Conference on Lung Cancer: VisionGate Will Present Twice!
VisionGate CEO Alan Nelson, PhD, and CMO Javier Zulueta,MD, to Present Two Pivotal Papers at the 17th World Conference on Lung Cancer
PHOENIX (November 17, 2016) – VisionGate®, Inc., a biotech company focused on the early detection and prevention of lung cancer, announced today that VisionGate has been invited to present two pivotal clinical studies at the International Association for the Study of Lung Cancer’s 17th World Conference on Lung Cancer in Vienna, Austria on December 5, 2016. VisionGate CEO Alan Nelson, PhD, will present a paper summarizing a blinded clinical study of the LuCED non-invasive test for the early detection of lung cancer. VisionGate CMO Javier Zulueta, MD, will present a paper summarizing the initial findings of the LuCED test in the detection of lung dysplasia, the pre-cancer condition targeted by the company’s drug Iloprost that has shown promise in a successful Phase II clinical trial. Nelson and Zulueta will present at the Messe Wien Exhibition & Congress Center beginning at approximately 11 a.m. CET as part of the session titled “Improvement and Implementation of Lung Cancer Screening”.
The IASLC World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries to discuss the latest developments in thoracic malignancy research. Attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses and allied health professionals and patients.
“We are thrilled to be presenting the encouraging data from our recent blinded trial of LuCED for the early detection of lung cancer and our recent study on detection of the pre-cancer condition called dysplasia,” Nelson said. “The World Conference on Lung Cancer is the place to learn about the most cutting-edge advancements in lung cancer, and we are proud to be part of that important discussion.”
For more information about VisionGate, please visit www.VisionGate3D.com.
VisionGate, Inc. is led by Dr. Alan Nelson, physicist, bioengineer and entrepreneur who previously developed the world’s first and only automated screening test to detect cervical cancer, marketed globally today as FocalPoint by Becton Dickinson. VisionGate’s proprietary LuCED test is a non-invasive diagnostic test for early-stage lung cancer, demonstrating exquisite sensitivity and specificity in blinded clinical studies. This physician-ordered, take-home sputum test is processed on the world’s first automated 3D cell imaging platform, the Cell-CT, named aptly because it is similar in principle to taking a CT scan of individual cells, but using visible light without harmful radiation. Moreover, with the new exclusive patent license from the University of Colorado for the drug called Iloprost, VisionGate will drive the therapeutic market for chemoprevention of lung cancer and, ultimately, the eradication of this killer. With 145 issued patents in 13 countries, VisionGate expects to play a leading role in the battle against the world’s number one cancer killer.